Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CNM-Au8

Other · developed by Clene Nanomedicine

Phase 2/3 Most advanced trial

CLNN Developer

2 Registered trials

What is CNM-Au8?

CNM-Au8 is an aqueous suspension of faceted gold nanocrystals, with gold atoms self-organized into crystals of various geometric shapes, taken orally once daily. It is studied in amyotrophic lateral sclerosis and relapsing multiple sclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Nanocrystalline gold, CNMAu8
Drug type: Other
Therapy area: Neurology
Developer: Clene Nanomedicine (CLNN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04626921	Phase 2/3	Relapsing Multiple Sclerosis	Completed	CLNN
NCT05299658	Phase 2	Amyotrophic Lateral Sclerosis	Active not recruiting	CLNN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Amyotrophic Lateral SclerosisRelapsing Multiple Sclerosis

More from Clene Nanomedicine

CNM-ZnAg Phase 2 Gold nanocrystals Phase 2

Sources

ClinicalTrials.gov NCT05299658

Updated Oct 11, 2026. Something wrong or missing? Report it on the CLNN page.

Follow CLNN, the company behind CNM-Au8

See CLNN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CLNN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z